Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC |
NATAN DAVIDDirector
|
GrantCommon Stock | 58,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-006206 · ownership.xml · nonDerivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,300 F1 · kind: Represents a stock award to the reporting person. Read SEC document |
| April 14, 2026 Filed Apr 14, 2026 20:26 UTC |
NATAN DAVIDDirector
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-002922 · ownership.xml · nonDerivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · kind: Represents a stock award to the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 16:05 UTC |
Slilaty Steve N.Director · Chief Executive Officer · 10% owner
|
PurchaseSeries B Preferred Stock | 100,000 | $0.10 | $10,000.00 |
DisclosureSEC source: 0001683168-24-001322 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:05 UTC |
Slilaty Steve N.Director · Chief Executive Officer · 10% owner
|
PurchaseSeries B Preferred Stock | 20,000 | $0.10 | $2,000.00 |
DisclosureSEC source: 0001683168-24-000879 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 06:01 UTC |
Sebaaly CamilleCFO/Secretary
|
PurchaseCommon Stock | 30,000 | $0.76 | $22,905.00 |
DisclosureSEC source: 0001683168-22-008144 · ownership.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,465 Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 12:36 UTC |
Sebaaly CamilleCFO/Secretary
|
PurchaseCommon Stock | 25,000 | $1.22 | $30,500.00 |
DisclosureSEC source: 0001683168-22-004178 · ownership.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,465 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 13:07 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
Disposition to issuerSeries B Preferred Stock | 990,000 | $0.10 | $99,000.00 |
DisclosureSEC source: 0001683168-22-001185 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: Dr. Slilaty returned 990,000 shares of Series B Preferred Stock to the Issuer for a redemption price equal to the stated value of $0.10 per share. Read SEC document |
| January 06, 2021 Filed Feb 16, 2021 12:30 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 20,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0001128732-21-000002 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,343,461 Read SEC document |
| January 06, 2021 Filed Feb 16, 2021 12:23 UTC |
Sebaaly CamilleDirector · CFO/Secretary
|
GrantCommon Stock | 20,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0001128732-21-000001 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,893,086 Read SEC document |
| January 06, 2021 Filed Feb 16, 2021 17:36 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 20,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0001128732-21-000003 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,342,500 Read SEC document |
| June 17, 2020 Filed Jun 25, 2020 14:19 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantSeries "B" Preferred Stock | 500,000 | $0.10 | $50,000.00 |
DisclosureSEC source: 0001128732-20-000002 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Read SEC document |
| December 31, 2019 Filed Jul 10, 2020 13:26 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
OtherCommon Stock | 323,673 | $0.00 | $323.67 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 3 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by TRT Pharma Inc., an entity controlled by the Reporting Person. Disclosed balance after: 861,209 F2 · kind: Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person. F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F2 · ownership.nature: Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person. Read SEC document |
| December 31, 2019 Filed Jul 15, 2020 12:09 UTC |
Sebaaly CamilleDirector · CFO/Secretary
|
GrantCommon Stock | 323,673 | $0.00 | $323.67 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 4 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · Held by TRT Pharma Inc. Disclosed balance after: 0 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F3 · ownership.nature: Effective December 31, 2019, 4019318 Canada, Inc., an entity controlled by the Reporting Person, effectuated a consolidation with Advanomics Corporation, an entity controlled by the Chief Executive Officer of the Issuer. The resulting consolidated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. and the Reporting Person no longer being a control person of TRT Pharma Inc. Read SEC document |
| December 19, 2019 Filed Jul 10, 2020 13:26 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 1,300,000 | $0.00 | $1,300.00 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 2 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,343,461 F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| December 19, 2019 Filed Jul 13, 2020 18:39 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 1,300,000 | $0.00 | $1,300.00 |
DisclosureSEC source: 0001128732-20-000004 · primary_doc.xml · nonDerivative · entry 2 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342,500 F1 · shares: The amount of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| December 19, 2019 Filed Jul 15, 2020 12:09 UTC |
Sebaaly CamilleDirector · CFO/Secretary
|
GrantCommon Stock | 1,300,000 | $0.00 | $1,300.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 3 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| October 20, 2019 Filed Jul 10, 2020 13:26 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 1,100,000 | $0.00 | $1,100.00 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,043,461 F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| October 20, 2019 Filed Jul 13, 2020 18:39 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 1,100,000 | $0.00 | $1,100.00 |
DisclosureSEC source: 0001128732-20-000004 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,042,500 F1 · shares: The amount of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| October 20, 2019 Filed Jul 15, 2020 12:09 UTC |
Sebaaly CamilleDirector · CFO/Secretary
|
GrantCommon Stock | 1,100,000 | $0.00 | $1,100.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 2 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| September 11, 2019 Filed Sep 23, 2019 09:56 UTC |
Sebaaly CamilleDirector · Secretary · 10% owner
|
GrantCommon Stock | 11,000,000 | $0.00 | $11,000.00 |
DisclosureSEC source: 0001128732-19-000025 · primary_doc.xml · nonDerivative · entry 2 Sebaaly Camille · CIK 0001474695 · Director · Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,861,719 Read SEC document |
| September 11, 2019 Filed Jul 15, 2020 12:09 UTC |
Sebaaly CamilleDirector · CFO/Secretary
|
GrantCommon Stock | 550,000 | $0.00 | $550.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F2 · shares: Shares issued by the Issuer to the Reporting Person for consulting services provided to the Issuer. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| September 02, 2019 Filed Sep 23, 2019 09:45 UTC |
Slilaty Steve N.Director · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 13,000,000 | $0.00 | $13,000.00 |
DisclosureSEC source: 0001128732-19-000024 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,869,219 F1 · balance_after: Effective February 1, 2019, the Issuer effectuated a reverse stock split wherein 1 share of Common Stock was issued for each 20 shares of the issued and outstanding Common Stock of the Issuer resulting in Reporting Person owning 5,869,219 shares of Common Stock of the Issuer as of that date. Read SEC document |
| September 02, 2019 Filed Sep 23, 2019 09:56 UTC |
Sebaaly CamilleDirector · Secretary · 10% owner
|
GrantCommon Stock | 13,000,000 | $0.00 | $13,000.00 |
DisclosureSEC source: 0001128732-19-000025 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,861,719 F1 · balance_after: Effective February 1, 2019, Issuer effectuated a reverse stock split wherein 1 share of Common Stock was issued for each 20 shares of the issued and outstanding Common Stock of the Issuer resulting in Reporting Person owning 5,861,719 shares of Common Stock of the Issuer as of that date. Read SEC document |
| September 02, 2019 Filed Oct 7, 2019 13:19 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 13,000,000 | $0.00 | $13,000.00 |
DisclosureSEC source: 0001128732-19-000032 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850,000 F1 · balance_after: Issuer effectuated a reverse stock split effective February 1, 2019 wherein one share of Common Stock of the Issuer was issued for each 20 shares of Common Stock issued and oustanding resulting in Reporting Person owning 5,850,000 shares of Common Stock of the Issuer as of that date. Read SEC document |
| August 27, 2018 Filed Sep 14, 2018 10:08 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-18-000011 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,384,373 Read SEC document |
| August 27, 2018 Filed Sep 14, 2018 10:14 UTC |
Sebaaly CamilleDirector · Secretary
|
GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-18-000012 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,234,373 Read SEC document |
| August 27, 2018 Filed Sep 14, 2018 14:23 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-18-000013 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,467,000 Read SEC document |
| August 27, 2018 Filed Oct 7, 2019 13:04 UTC Amendment |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-19-000031 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,000,000 Read SEC document |
| June 20, 2018 Filed Jun 28, 2018 17:47 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-18-000006 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,384,373 Read SEC document |
| June 20, 2018 Filed Jun 28, 2018 17:52 UTC |
Sebaaly CamilleDirector · Secretary
|
GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-18-000007 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,234,373 Read SEC document |
| June 20, 2018 Filed Jun 28, 2018 21:57 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-18-000008 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,467,000 Read SEC document |
| June 20, 2018 Filed Oct 7, 2019 12:55 UTC Amendment |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-19-000030 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000,000 Read SEC document |
| April 22, 2018 Filed Oct 4, 2019 15:57 UTC Amendment |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 12,000,000 | $0.00 | $12,000.00 |
DisclosureSEC source: 0001128732-19-000027 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000,000 Read SEC document |
| July 20, 2017 Filed Sep 8, 2017 09:28 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-17-000031 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,384,373 Read SEC document |
| July 20, 2017 Filed Sep 8, 2017 09:45 UTC |
Sebaaly CamilleDirector · Secretary
|
GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-17-000032 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,234,373 Read SEC document |
| July 20, 2017 Filed Sep 8, 2017 13:55 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-17-000033 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,467,000 Read SEC document |
| July 20, 2017 Filed Oct 4, 2019 23:10 UTC Amendment |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-19-000029 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000,000 Read SEC document |
| December 06, 2016 Filed Dec 15, 2016 19:45 UTC |
Slilaty Steve N.Director · Chief Executive Officer
|
GrantCommon Stock | 26,000,000 | $0.00 | $26,000.00 |
DisclosureSEC source: 0001128732-16-000036 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,384,373 Read SEC document |
| December 06, 2016 Filed Dec 15, 2016 19:50 UTC |
Sebaaly CamilleDirector · CFO and Secretary
|
GrantCommon Stock | 26,000,000 | $0.00 | $26,000.00 |
DisclosureSEC source: 0001128732-16-000037 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234,373 Read SEC document |
| December 06, 2016 Filed Dec 16, 2016 00:58 UTC |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 26,000,000 | $0.00 | $26,000.00 |
DisclosureSEC source: 0001128732-16-000038 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,467,000 Read SEC document |
| December 06, 2016 Filed Oct 4, 2019 23:03 UTC Amendment |
MERZOUKI ABDERRAZZAKDirector · Chief Operating Officer
|
GrantCommon Stock | 28,000,000 | $0.00 | $28,000.00 |
DisclosureSEC source: 0001128732-19-000028 · primary_doc.xml · nonDerivative · entry 1 MERZOUKI ABDERRAZZAK · CIK 0001636418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000,000 Read SEC document |
| October 10, 2016 Filed Nov 7, 2016 12:01 UTC |
Sebaaly CamilleDirector · CFO and Secretary · 10% owner
|
OtherCommon Stock | 129,468,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001128732-16-000031 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by 4019318 Canada Inc., an entity controlled by Reporting Person. Disclosed balance after: 129,468,927 F1 · kind: 129,468,927 shares were acquired by 4019318 Canada Inc., an entity controlled by Reporting Person, pursuant to a share exchange with an unrelated entity; no consideration was paid as a result of the share exchange. F1 · price: 129,468,927 shares were acquired by 4019318 Canada Inc., an entity controlled by Reporting Person, pursuant to a share exchange with an unrelated entity; no consideration was paid as a result of the share exchange. Read SEC document |
| October 10, 2016 Filed Nov 7, 2016 11:41 UTC |
Slilaty Steve N.Director · Chief Executive Officer · 10% owner
|
OtherCommon Stock | 136,861,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001128732-16-000030 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Advanomics Corporation, an entity controlled by Reporting Person. Disclosed balance after: 215,014,224 F1 · kind: 136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange. F1 · price: 136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange. Read SEC document |
| October 10, 2016 Filed Nov 7, 2016 17:10 UTC |
Advanomics Corp10% owner
|
OtherCommon Stock | 136,861,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001128732-16-000032 · primary_doc.xml · nonDerivative · entry 1 Advanomics Corp · CIK 0001681176 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,014,224 F1 · kind: 136,861,968 shares were disposed of pursuant to a share exchange with an unrelated entity; no consideration was received as a result of the share exchange. F1 · price: 136,861,968 shares were disposed of pursuant to a share exchange with an unrelated entity; no consideration was received as a result of the share exchange. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.